Perceptions of Orthopaedic Sports Medicine Surgeons About Medical Cannabidiol Use: A Survey Study
Orthopaedic Surgery, Cedars-Sinai Kerlan-Jobe Institute, Los Angeles, USA
Abstract
Introduction: Multiple studies exist identifying cannabidiol (CBD) as an effective part of an orthopaedic patient’s pain regimen; however, there is a paucity of studies elucidating orthopaedic surgeons' perception of the use and prescription of CBD in the medical setting. This study surveys orthopaedic sports medicine surgeons about their previous education on and current perceptions and usage of CBD in their medical practice.
Methods: Between April 2023 and July 2023, orthopaedic sports medicine surgeons from across the country were surveyed. This survey was designed in hopes of identifying physician perceptions and current use of CBD as well as their previous education and training on its use.
Results: Overall, 75 orthopaedic surgeons responded. More than three-fourths of responders had not received formal education on medical CBD use, nor did they have partners or colleagues who used CBD in their practice. More than half of all surgeons believed that there is a stigma associated with CBD use. A higher proportion of surgeons from CBD legal states recommended CBD to help patients control their pain (53.7% vs. 37.5%). Less than 15% of responders believed that CBD can adversely affect surgical outcomes. Finally, four-fifths of all responders believed that CBD is easy to legally access and affordable to buy by patients who desire it.
Discussion: The relative novelty of CBD inclusion in medicine has led to a lack of early education and overall experience with its use among orthopaedic sports medicine surgeons. Still, surgeons believe that CBD is a safe and effective option to control pain. As surgeons continue to gain more familiarity and trust with CBD’s medical uses over time, it has the potential to be a mainstay in orthopaedic multimodal pain regimens.
Untitled section
Keywords: medical education, pain regimen, cbd awareness, opioid-sparing analgesia, orthopedic sports medicine, orthopaedic surgery, cannabidiol (cbd)
Article notes
Untitled section
Accepted 2023 Nov 21; Collection date 2024 Jan.
Introduction
The legalization of marijuana or Cannabis sativa and Cannabis indica across the United States has led to its recent incorporation into healthcare. Marijuana has two main components, tetrahydrocannabinol (THC) and cannabidiol (CBD), which can both be isolated and applied. Via cannabinoid receptors both in the brain and peripheral tissue, THC increases dopamine and produces psychotropic effects [1], leading to both recreational and entheogenic utilization. In contrast, CBD has been shown to act on opioid receptors [2], potentially providing analgesia without the psychoactive effects. This has led to its utilization across various medical fields as part of a multimodal pain regimen aimed at better controlling pain and decreasing opioid use in the face of the opioid pandemic [3].
Due to multiple factors, including recent legalization and publicity [4], marijuana use has been increasing over the past 20 years [5]. Its potential to help with nausea, vomiting, and other symptoms with relative safety has increased its medical uses over the years [6]. This has even led to the classification of Epidiolex®, a CBD product as a generally recognized as safe (GRAS) product for medical use by the United States Food and Drug Administration (FDA). However, CBD’s analgesic effects have garnered the most attention and are its most common reason for usage, with both oral and topical forms commonly utilized. Medical marijuana is legal in 37 states, three territories, and the District of Columbia [7], making medical CBD use an evolving and important pain control option to consider. Orthopaedic patient pain has often been cited as one of the hardest to control [8], making CBD a natural target to utilize in hopes of better closing the gap between patient-perceived pain levels and overall pain control [9].
Multiple studies exist identifying CBD as an effective part of an orthopaedic patient’s pain regimen, both in treating pain secondary to non-operative conditions [10] and postoperative pain [11]; however, there is a paucity of studies elucidating orthopaedic surgeons' perceptions about the use and prescription of CBD in the medical setting. While 88% of trauma surgeons who were surveyed as part of the Orthopaedic Trauma Association (OTA) did not believe they were knowledgeable about the mechanism of CBD, 73% believed it could help control postoperative pain [12]. Unfortunately, no similar study exists to elucidate physician perceptions on CBD use among orthopaedic sports medicine surgeons. Therefore, this study seeks to survey orthopaedic sports medicine surgeons to identify previous education on and current perceptions and usage of CBD in their medical practice.
Materials and methods
Approval for this cross-sectional survey study was given by the Cedars-Sinai Institutional Review Board (approval number: STUDY00002418). From April 2023 to July 2023, all orthopaedic sports medicine surgeons who were part of the American Orthopaedic Society of Sports Medicine (AOSSM) as well as surgeons from a large sports medicine fellowship alumni network (with multiple surgeons in every geographic region) were surveyed. All surveys that were completed were included in the study. This survey was designed in hopes of identifying physician perceptions and current use of CBD as well as their previous education and training on its use (See Appendices). This survey was constructed utilizing previously published surveys exploring patient CBD use [13-15]. The survey was distributed online utilizing REDCap web application (Vanderbilt Institute for Clinical and Translational Research, Nashville, Tennessee, United States).
The first section of the survey asked questions about surgeon demographics, including practice location and total years in practice. The next section asked whether surgeons were educated on CBD use in their medical training and if they have experience with its use in practice (by them or their colleagues). Surgeons are also asked if they believe there is a stigma associated with the medical use of CBD. Finally, surgeons are asked if they believe CBD use is effective in controlling pain and other pathologies (sleep and anxiety), whether certain forms of CBD are more effective than others, and whether CBD use can negatively affect patient outcomes. Data was recorded using REDCap [16,17]. Survey answers were analyzed utilizing descriptive statistics using IBM SPSS Statistics for Windows, Version 23.0 (Released 2015; IBM Corp., Armonk, New York, United States). For all analyses, statistical significance was set at p < 0.05.
Results
Overall, 75 orthopaedic surgeons responded to our survey. Sixty-seven (89.3%) of these surgeons were from states where the medical use of CBD is legal. Most surgeons were either five or fewer years into practice and in private practice. There were also 13 surgeons who believed the medical use of CBD in their state was not legal when it truly was (Table 1).
| Medical CBD Legal States | Medical CBD Non-Legal States | Total | ||
| Years in Practice | <5 years | 24 (35.8%) | 3 (37.5%) | 27 (36.0%) |
| 6-10 years | 8 (11.9%) | 1 (12.5%) | 9 (12.0%) | |
| 11-20 years | 15 (22.4%) | 1 (12.5%) | 16 (21.3) | |
| 21+ years | 20 (29.9%) | 3 (37.5%) | 23 (30.7%) | |
| Type of Practice | Academic | 11 (16.4%) | 4 (50.0%) | 15 (20.0%) |
| Hospital Employed | 20 (29.9%) | 0 (0.0%) | 20 (26.7%) | |
| Private Practice | 36 (53.7%) | 4 (50.0%) | 40 (53.3%) | |
| Belief in State CBD Legality | Yes | 54 (80.6%) | 0 (0.0%) | 54 (72.0%) |
| No | 13 (19.4%) | 8 (100.0%) | 21 (28.0%) | |
| Total | 67 | 8 | 75 | |
More than 80% of orthopaedic surgeons from CBD legal states have not received formal education about medical CBD use, nor have they ever seen CBD used in their training. In CBD non-legal states, 62.5% (n=5) of surgeons have not received formal education about medical CBD use, while 75.0% (n=6) of surgeons have never seen CBD used in their training. About three-fourths of responders in both CBD legal and non-legal states did not have partners or colleagues that used CBD in their practice either. Finally, 58.2% (n=39) of surgeons from CBD legal states and 50.0% (n=4) of surgeons from CBD non-legal states believed that there is a stigma associated with CBD use (Table 2).
| Medical CBD Legal States | Medical CBD Non-Legal States | Total | ||
| Have you received formal education about CBD and its medical uses? | Yes | 6 (9.0%) | 3 (37.5%) | 9 (12.0%) |
| No | 61 (91.0%) | 5 (62.5%) | 66 (88.0%) | |
| Did you ever see CBD used in your training? | Yes | 11 (16.4%) | 2 (25.0%) | 13 (17.3%) |
| No | 56 (83.6%) | 6 (75.0%) | 62 (82.7%) | |
| Do your partners or colleagues use CBD in their practice for pain control? | Yes | 14 (20.9%) | 2 (25.0%) | 16 (21.3%) |
| No | 53 (79.1%) | 6 (75.0%) | 59 (78.7%) | |
| Do you believe there is a stigma for using CBD (as a provider or for patients)? | Yes | 39 (58.2%) | 4 (50.0%) | 43 (57.3%) |
| No | 28 (41.8%) | 4 (50.0%) | 32 (42.7%) | |
| Total | 67 | 8 | 75 | |
A higher proportion of surgeons from CBD legal states recommend CBD to help patients control their pain (53.7% vs. 37.5%). Slightly more surgeons from these states also thought there is a role for CBD in managing postoperative pain (58.2% vs. 50.0%), acute traumatic pain (41.8% vs. 37.5%), and chronic pain (91.0% vs. 75.0%). Additionally, very few surgeons prescribed CBD to help with sleep (1.5% vs. 0.0%) or anxiety (3.0% vs. 12.5%) (Figure 1).
While 40.3% (n=27) of responders in CBD legal states and 37.5% (n=3) of responders in CBD non-legal states believed that certain forms of CBD are more effective than others, there was no consensus among surgeons about which forms are more effective (Figure 2). Only 13.4% (n=9) of responders in CBD legal states and 12.5% (n=1) of responders in CBD non-legal states believed that CBD can adversely affect surgical outcomes, with less than 10% of responders noting that they believe CBD affects bone and wound healing, that it can cause ineffective pain control, and that it can cause habituation (Figure 3). Finally, a high percentage of responders in both CBD legal and non-legal states believed that CBD was easy to legally access for patients who desire to (83.6% vs. 87.5%) and is affordable to buy by patients who desire to (79.1% vs. 87.5%).
Discussion
As CBD use in society increases in conjunction with increased legality laws, physicians must continue to explore the role of medical CBD in patient care. Current laws designate CBD as either conditionally legal or fully legal in all 50 states, allowing for increased CBD production as well as access for physicians and patients. CBD presents an intriguing option as part of a multimodal pain regimen with the goal of decreasing narcotic use in the face of the opioid pandemic [18]. However, physician education about and experience with CBD use is lacking, mostly due to the relative novelty of CBD legality. Still, responding surgeons believed both that there is a role for CBD in controlling chronic pain and that CBD use is relatively safe.
CBD education should start in the early stages of provider training in order to broaden understanding and experience over time. However, given the relatively new changes in CBD legality laws across the country [19], it has still not reliably become a part of medical education [20,21]. Responding physicians to our survey also had limited education and experience with CBD, both in training and in practice, a fact echoed in Chin et al.’s survey querying OTA members [12]. However, as CBD use continues to increase, hopefully so will early trainee education as well as overall physician comfort. This has the potential to decrease the overall stigma associated with its use, both among providers and patients.
Most surgeons did believe that CBD does have a place in treating pain, specifically chronic pain. This was also echoed by OTA members [12]. CBD’s efficacy in treating acute and chronic pain has been well established in the literature [11]. CBD does represent an effective alternative to narcotic medication to treat all types of pain, and all physicians should consider CBD in pain regimens in the right patient. In addition, only a few surgeons utilized CBD to treat sleep or anxiety, a use that has been well studied in the literature [22,23]. As CBD use becomes more prevalent in the face of increased state legality laws, we may see an increase in CBD use in various fields and for various uses.
Overall, most surgeons felt that certain forms of CBD are more effective than others, even if there was no consensus on which form was superior. Goodman et al. found that patients turn to various types of forms of CBD, but research on the effectiveness of each form is lacking [24]. Physicians and patients must consider ease of use, cost, and accessibility when deciding which forms of CBD to utilize. In addition, most surgeons believe that CBD use is overall safe, a finding well documented in the literature [25,26]. This has led to the GRAS status of Epidiolex (an oral solution), a status that may extend to multiple other products as CBD use continues to increase. However, surgeons should still be aware of and counsel patients on possible orthopaedic side effects associated with CBD use, including increased time to fracture union, wound healing, and other surgical complications [27-29]. Surgeons should also consider the effect CBD may have on habituation and mental health when considering utilizing CBD as part of their patients’ pain regimen plan [29].
Finally, the vast majority of surgeons in the current study, regardless of CBD legality in their state, believed that CBD was both affordable and easy to access for patients. While studies have documented relatively low costs for CBD ($3.68-14.71 USD, per 100mg [30]), this cost can be variable by region. Over time, this has the potential to cause a significant financial burden on patients. In addition, while surgeons do believe that CBD is accessible to their patients, they should continue to be wary of all the illegal channels that exist for CBD obtainment.
Limitations of this study are those that are inherent to a survey study. Only AOSSM members were surveyed, not allowing surgeons who are not a part of this society a chance to complete this survey. Since surveys were distributed through the AOSSM website, a true responder rate cannot be identified. There were also only a few orthopaedic surgeons who practised in CBD non-legal states that filled out this survey, a bias that could affect these results. This also precluded a comparison between responders from CBD legal and non-legal states. These two factors led to a small overall sample size. In addition, the accuracy of these answers among responders, especially by responders from CBD non-legal states, cannot be confirmed. Finally, the lack of FDA approval of CBS use for medical pain limits the ease of the completion of future studies unless these studies are FDA approved.
Conclusions
The relative novelty of CBD inclusion in medicine has led to a lack of early education and overall experience with its use among orthopaedic sports medicine surgeons. Still, surgeons believe that CBD is a safe and effective option to control pain. Increased early education as well as continued research into the therapeutic roles of CBD can help increase its medical usage and hopefully decrease the need for opioid analgesics. As surgeons continue to gain more familiarity and trust with CBD’s medical uses over time, it has the potential to be a mainstay in orthopaedic multimodal pain regimens.
Appendices
Untitled section
Untitled section
Footnote Group
Human Ethics
Footnote Group
Animal Ethics
Footnote Group
References
Untitled section
References
- 1.A brain on cannabinoids: the role of dopamine release in reward seeking. Oleson EB, Cheer JF. Cold Spring Harb Perspect Med. 2012;2 doi: 10.1101/cshperspect.a012229.
- 2.Cannabidiol is an allosteric modulator at mu- and delta-opioid receptors. Kathmann M, Flau K, Redmer A, Tränkle C, Schlicker E. Naunyn Schmiedebergs Arch Pharmacol. 2006;372:354–361. doi: 10.1007/s00210-006-0033-x.
- 3.State medical cannabis laws associated with reduction in opioid prescriptions by orthopaedic surgeons in Medicare Part D cohort. Lopez CD, Boddapati V, Jobin CM, Hickernell TR. J Am Acad Orthop Surg. 2021;29:0–97. doi: 10.5435/JAAOS-D-19-00767.
- 4.Trends in internet searches for cannabidiol (CBD) in the United States. Leas EC, Nobles AL, Caputi TL, Dredze M, Smith DM, Ayers JW. JAMA Netw Open. 2019;2:0. doi: 10.1001/jamanetworkopen.2019.13853.
- 5.Has self-reported marijuana use changed in patients undergoing total joint arthroplasty after the legalization of marijuana? Jennings JM, Williams MA, Levy DL, Johnson RM, Eschen CL, Dennis DA. Clin Orthop Relat Res. 2019;477:95–100. doi: 10.1097/CORR.0000000000000339.
- 6.Therapeutic efficacy of cannabidiol (CBD): a review of the evidence from clinical trials and human laboratory studies. Sholler DJ, Schoene L, Spindle TR. Curr Addict Rep. 2020;7:405–412. doi: 10.1007/s40429-020-00326-8.
- 7.National Conference of State Legislatures. State Medical Cannabis Laws. [ Jul; 2023 ]. 2023. https://www.ncsl.org/health/state-medical-cannabis-laws https://www.ncsl.org/health/state-medical-cannabis-laws
- 8.The opioid epidemic: impact on orthopaedic surgery. Morris BJ, Mir HR. J Am Acad Orthop Surg. 2015;23:267–271. doi: 10.5435/JAAOS-D-14-00163.
- 9.Cannabinoids and orthopedic surgery: a systematic review of therapeutic studies. Vivace BJ, Sanders AN, Glassman SD, Carreon LY, Laratta JL, Gum JL. J Orthop Surg Res. 2021;16:57. doi: 10.1186/s13018-021-02205-y.
- 10.The effects of cannabinoid use on acute orthopaedic pain. Morrow M. J Orthop Physician Assist. 2020;8:0.
- 11.Buccally absorbed cannabidiol shows significantly superior pain control and improved satisfaction immediately after arthroscopic rotator cuff repair: a placebo-controlled, double-blinded, randomized trial. Alaia MJ, Hurley ET, Vasavada K, et al. Am J Sports Med. 2022;50:3056–3063. doi: 10.1177/03635465221109573.
- 12.Knowledge and opinion on cannabinoids among orthopaedic traumatologists. Chin G, Etiz BA, Nelson AM, Lim PK, Scolaro JA. J Am Acad Orthop Surg Glob Res Rev. 2021;5 doi: 10.5435/JAAOSGlobal-D-21-00047.
- 13.The emerging role of cannabidiol (CBD) products; a survey exploring the public's use and perceptions of CBD. Bhamra SK, Desai A, Imani-Berendjestanki P, Horgan M. Phytother Res. 2021;35:5734–5740. doi: 10.1002/ptr.7232.
- 14.Prevalence of cannabinoid use in patients with hip and knee osteoarthritis. Deckey DG, Lara NJ, Gulbrandsen MT, Hassebrock JD, Spangehl MJ, Bingham JS. J Am Acad Orthop Surg Glob Res Rev. 2021;5 doi: 10.5435/JAAOSGlobal-D-20-00172.
- 15.Prevalence of cannabinoid (CBD) use in orthopaedic sports medicine patients. Deckey DG, Doan M, Hassebrock JD, et al. Orthop J Sports Med. 2022;10:23259671221087629. doi: 10.1177/23259671221087629.
- 16.The REDCap consortium: building an international community of software platform partners. Harris PA, Taylor R, Minor BL, et al. J Biomed Inform. 2019;95:103208. doi: 10.1016/j.jbi.2019.103208.
- 17.Research electronic data capture (REDCap)--a metadata-driven methodology and workflow process for providing translational research informatics support. Harris PA, Taylor R, Thielke R, Payne J, Gonzalez N, Conde JG. J Biomed Inform. 2009;42:377–381. doi: 10.1016/j.jbi.2008.08.010.
- 18.Comprehensive analysis of opioid use after common elective outpatient orthopaedic surgeries. Okoli MU, Rondon AJ, Townsend CB, Sherman MB, Ilyas AM. J Am Acad Orthop Surg Glob Res Rev. 2022;6 doi: 10.5435/JAAOSGlobal-D-21-00226.
- 19.Education and attitudes on medical cannabis in family medicine residency programs. Philbrick AM, Danner C, Oyenuga A, Pereira C, Ricco J, Wendling AL. Fam Med. 2020;52:730–735. doi: 10.22454/FamMed.2020.645274.
- 20.Physicians-in-training are not prepared to prescribe medical marijuana. Evanoff AB, Quan T, Dufault C, Awad M, Bierut LJ. Drug Alcohol Depend. 2017;180:151–155. doi: 10.1016/j.drugalcdep.2017.08.010.
- 21.Medicinal cannabis: a survey among health care providers in Washington state. Carlini BH, Garrett SB, Carter GT. Am J Hosp Palliat Care. 2017;34:85–91. doi: 10.1177/1049909115604669.
- 22.Cannabinoid therapies in the management of sleep disorders: a systematic review of preclinical and clinical studies. Suraev AS, Marshall NS, Vandrey R, et al. Sleep Med Rev. 2020;53:101339. doi: 10.1016/j.smrv.2020.101339.
- 23.Use of cannabidiol in anxiety and anxiety-related disorders. Skelley JW, Deas CM, Curren Z, Ennis J. https://www.sciencedirect.com/science/article/abs/pii/S154431911930514X. J Am Pharm Assoc (2003) 2020;60:253–261. doi: 10.1016/j.japh.2019.11.008.
- 24.Use and perceptions of cannabidiol products in Canada and in the United States. Goodman S, Wadsworth E, Schauer G, Hammond D. Cannabis Cannabinoid Res. 2022;7:355–364. doi: 10.1089/can.2020.0093.
- 25.Multicenter, double-blind, randomized, placebo-controlled, parallel-group study of the efficacy, safety, and tolerability of THC:CBD extract and THC extract in patients with intractable cancer-related pain. Johnson JR, Burnell-Nugent M, Lossignol D, Ganae-Motan ED, Potts R, Fallon MT. J Pain Symptom Manage. 2010;39:167–179. doi: 10.1016/j.jpainsymman.2009.06.008.
- 26.Cannabidiol drugs clinical trial outcomes and adverse effects. Pauli CS, Conroy M, Vanden Heuvel BD, Park SH. Front Pharmacol. 2020;11:63. doi: 10.3389/fphar.2020.00063.
- 27.Marijuana use results in increased time to union in surgically treated pediatric fracture patients. Heath D, Ghali A, Momtaz D, Lee L, Hogue G. J Orthop Trauma. 2022;36:0–10. doi: 10.1097/BOT.0000000000002242.
- 28.Marijuana in orthopaedics: effects on bone health, wound-healing, surgical complications, and pain management. Heath DM, Koslosky EJ, Bartush KC, Hogue GD. JBJS Rev. 2022;10 doi: 10.2106/JBJS.RVW.21.00184.
- 29.Impact of pre-operative recreational marijuana use on outcomes two years after orthopaedic surgery. Albelo FD, Baker M, Zhang T, et al. Int Orthop. 2021;45:2483–2490. doi: 10.1007/s00264-021-05069-3.
- 30.Cannabidiol use and effectiveness: real-world evidence from a Canadian medical cannabis clinic. Rapin L, Gamaoun R, El Hage C, Arboleda MF, Prosk E. J Cannabis Res. 2021;3:19. doi: 10.1186/s42238-021-00078-w.